Abiopharma

🔍 TYSOE RONALD W (Director)

Company: CINTAS CORP (CTAS)

Report Date: 2026-04-20

Detailed Transactions and Holdings:

• Acquired 5,500 shares of Common Stock at $27.1 per share (Direct)
  Date: 2026-04-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 27,948.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 834 shares of Common Stock at $178.83 per share (Direct)
  Date: 2026-04-20 | Code: F | equity_swap_involved: 0 | shares_owned_after: 27,114.00 | transaction_form_type: 4
• Sold 4,666 shares of Common Stock at $178.87 per share (Direct)
  Date: 2026-04-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 22,448.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 5,500 shares of Stock Option (Right to Buy) at $27.1 per share (Derivative)
  Date: 2026-04-20 | Code: M | Expires: 2026-10-18 | Exercise: 2017-10-18 | equity_swap_involved: 0 | shares_owned_after: 5,048.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F1, F1

Footnotes:

• F1: On September 4, 2024, Cintas Corporation completed a four-for-one stock split of its common stock. All share amounts and exercise prices have been adjusted to give effect to this stock split.
• F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $178.82 to $178.97. The Reporting Person undertakes to provide full pricing information to the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission upon request.
• F3: Option granted pursuant to Cintas Corporation's 2016 Equity Compensation Plan. These shares were fully vested as of the first anniversary of the grant date.